Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly

NCT01221103 is registered in ClinicalTrials.gov with Southern Europe New Drug Organization as lead sponsor.

NCT NCT01221103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01221103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly
Lead sponsor
Southern Europe New Drug Organization
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 30, 2010
Completion date
June 30, 2012
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, mantle-cell